Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.57 |
| ▸ | F10 | P00742 | 7/20 | 0.57 |
| ▸ | PLG | P00747 | 7/20 | 0.57 |
| ▸ | PLAU | P00749 | 7/20 | 0.57 |
| ▸ | PLAT | P00750 | 7/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 9/20 | 0.51 |
| ▸ | F9 | P00740 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962621 | 0.91 | HDAC6 (0.56) | F2F10PLGPLAUPLAT | |
| SCHEMBL4964321 | 0.90 | HDAC6 (0.57) | F2F10PLGPLAUPLAT | |
| SCHEMBL4963154 | 0.89 | HDAC6 (0.60) | F2F10PLGPLAUPLAT | |
| SCHEMBL4965539 | 0.88 | HDAC6 (0.61) | F2F10PLGPLAUPLAT | |
| SCHEMBL4964237 | 0.88 | HDAC6 (0.53) | F2F10PLGPLAUPLAT | |
| SCHEMBL1509635 | 0.85 | CHEK2 (0.53) | F2F10PLGPLAUPLAT | |
| SCHEMBL4963557 | 0.83 | PDE10A (0.47) | F2F10PLGPLAUPLAT | |
| SCHEMBL4962190 | 0.80 | HDAC6 (0.51) | F2F10PLGPLAUPLAT | |
| SCHEMBL4961386 | 0.79 | HDAC6 (0.47) | F2F10PLGPLAUPLAT | |
| SCHEMBL4963532 | 0.79 | HDAC6 (0.50) | F2F10PLGPLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | F2 2487/4885F10 3867/4885PLG 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.